About Generation Bio
Generation Bio is a company based in Cambridge (United States) founded in 2016 by Phillip Samayoa and Mark Angelino was acquired by XOMA Corporation in December 2025. Generation Bio has raised $236.47 million across 3 funding rounds from investors including Fidelity Investments, T. Rowe Price and Farallon Capital Management. The company has 115 employees. Generation Bio offers products and services including ctLNP-siRNA. Generation Bio operates in a competitive market with competitors including Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
- Headquarter Cambridge, United States
- Employees 115
- Founders Phillip Samayoa, Mark Angelino
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website generationbio.com
- Social LinkedIn X
- Acquired by XOMA Corporation (Dec 2025)
- Legal Name Generation Bio Co.
- Annual Revenue$19.89 M (USD)236.92as on Dec 31, 2024
- Net Profit-$131.67 M (USD)-3.99as on Dec 31, 2024
- EBITDA-$73.41 M (USD)41.87as on Dec 31, 2024
- Total Equity Funding$236.47M (USD)
in 3 rounds
- Latest Funding Round$111.47M (USD), Series C
Jan 2020
- InvestorsFidelity Investments
& 10 more
- Employee Count115
- Acquired byXOMA Corporation
(Dec 2025)
Products & Services of Generation Bio
Generation Bio offers a comprehensive portfolio of products and services, including ctLNP-siRNA.
Delivers siRNA to T cells for treating autoimmune diseases
Funding Insights of Generation Bio
Generation Bio has successfully raised a total of $236.47M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $111.47 million completed in January 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $236.47M
- Total Rounds 3
- Last Round Series C — $111.47M
- First Round $25M
(Jan 2018)
- Investors Count 10
All 3 funding rounds of Generation Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan 2020 | $111.47M | Series C | – | T. Rowe Price | |
| Feb 2018 | $100M | Series B | – | Fidelity Investments | |
| Jan 2018 | $25M | Series A | – | – |
11 investors in total: 11 institutional.
Investors in Generation Bio
Generation Bio has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Fidelity Investments, T. Rowe Price and Farallon Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm investing in life science and biotechnology sectors | 1980 | atlasventure.com | Cambridge, United States | |
Multiple investment strategies are pursued by this hedge fund. | 1986 | faralloncapital.com | San Francisco, United States | |
Long-term private equity investments in transformational opportunities are pursued. | – | invus.com | New York, United States | |
Investing in Life Sciences sectors like Healthcare and Biotechnology. | – | casdincapital.com | - | |
Healthcare ecosystem is supported through investment and innovation by Deerfield. | – | deerfield.com | New York, United States | |
Multi-stage investment firm invests in healthcare and life sciences companies | – | foresitecapital.com | New York, United States | |
Diversified asset management services are provided to investors globally. | 1937 | troweprice.com | Baltimore, United States | |
Diversified investment management services are provided to institutional clients. | – | wellington.com | Boston, United States | |
Provider of brokerage accounts, retirement planning, wealth management, and trading platforms | 1946 | fidelity.com | Boston, United States | |
M&A advisory services are provided for healthcare companies. | 1995 | svbsecurities.com | Boston, United States |
Investor details for Generation Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Generation Bio
16 people are tracked at Generation Bio (3 in leadership, 13 in board & advisors); the tracked headcount is 115.
| Name | Role | Group |
|---|---|---|
Phillip Samayoa | Co-Founder | Leadership |
Mark Angelino | Co-Founder & COO | Leadership |
Geoff McDonough | CEO | Leadership |
Gustav Christensen | Director | Board & advisors |
Charles Rowland | Director | Board & advisors |
Richard Thompson | Advisor | Board & advisors |
Donald Nicholson | Director | Board & advisors |
Catherine Stehman-Breen | Director | Board & advisors |
Adrian Thrasher | Advisor | Board & advisors |
Katherine Fitzgerald | Advisor | Board & advisors |
Kevin Fitzgerald | Advisor | Board & advisors |
Ron Cooper | Director | Board & advisors |
Jason Rhodes | Chair | Board & advisors |
Jeff Jonas | Director | Board & advisors |
Anthony Quinn | Director | Board & advisors |
Steven Dowdy | Advisor | Board & advisors |
Complete people profiles for Generation Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Generation Bio
Generation Bio is a publicly listed company on the NASDAQ with ticker symbol GBIO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date12 Jun 2020
- Listed onNASDAQ: GBIO
- Listed entityGeneration Bio Co.
- Exchange sectorHealth technology
- ISINUS37148K2096
- Share price$5.34 (-6.97% on the day) · 2026-02-10
- Market capitalisation$36.0M
- EPS (diluted, trailing year)$-9.35
- Volume (last session)551,924
- Analyst consensusBuy
Financials of Generation Bio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2024 | $19.9M | -$131.7M | -$73.4M |
| 2023 | $5.9M | -$126.6M | -$126.3M |
| 2022 | – | -$136.6M | -$130.9M |
| 2021 | – | -$119.2M | -$114.6M |
| 2020 | – | -$80.5M | -$77.7M |
Detailed financial statements for Generation Bio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Generation Bio
5 dated milestones of Generation Bio across 9 years, from founding to its latest funding, stage changes and deals.
- Founded Generation Bio is founded.
- Funding First funding round of $25.0M.
- Funding Latest funding round, Series C, of $111.5M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by XOMA Corporation.
Competitors of Generation Bio
Generation Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BridgeBio, Spark Therapeutics, Alnylam and ATAI, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| rhythmtx.com | 2010 | Boston, United States | $84M | 115 | Developer of peptide therapeutics for the treatment of rare genetic deficiencies | |
| horizontherapeutics.com | 2008 | Dublin, Ireland | $61.78M | – | Developer of drugs for treating rare and autoimmune diseases | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. |
Detailed competitors of Generation Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Generation Bio
The website of Generation Bio (generationbio.com) receives about 4.1K visits a month and ranks #4,660,703 among all websites worldwide, #5,548 in Biotechnology and Pharmaceuticals.
- Monthly visits4.1K
▲ 12.5% vs previous month
- Unique visitors1.6K
per month
- Global rank#4,660,703
among all websites
- Category rank#5,548
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit1.8
- Average visit34 sec
- DevicesDesktop 41% · Mobile 59%
Latest news on Generation Bio
Complete news archive for Generation Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Generation Bio
10 companies that operate in the same segment as Generation Bio (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Generation Bio
Generation Bio was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Generation Bio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Geoff McDonough is the current CEO of Generation Bio.
Generation Bio is a funded company, having raised a total of $236.47M across 3 funding rounds to date. The company's 1st funding round was a Series A of $25M, raised on Jan 2018.
Generation Bio has 115 employees.
Annual revenue of Generation Bio is $19.89M as on Dec 31, 2024.
Generation Bio was founded in 2016 in Cambridge, United States, within the biotechnology sector. Non-viral gene therapies are provided for conditions such as phenylketonuria, hemophilia A, Wilson disease, Leber congenital amaurosis, and Stargardt disease. The Gene Wave technology enables optimal titration and re-dosing through closed-ended DNA. This ceDNA is packaged in lipid nanoparticles, which dissolve into cell cytoplasm and enter the nucleus to produce proteins.
Generation Bio's top competitors include Moderna, Spark Therapeutics and BridgeBio.
Generation Bio offers ctLNP-siRNA.
Yes, Generation Bio is publicly traded on NASDAQ under the ticker symbol GBIO.
Generation Bio has 11 investors. Key investors include Fidelity Investments, T. Rowe Price, Farallon Capital Management, Atlas Venture, and XOMA Corporation.
Generation Bio operates through Generation Bio Co..